Cliniccare Laboratories, Llc

CLIA Laboratory Citation Details

2
Total Citations
8
Total Deficiencyies
3
Unique D-Tags
CMS Certification Number 26D2240325
Address 1310 Papin Street Suite 107b, Saint Louis, MO, 63103
City Saint Louis
State MO
Zip Code63103
Phone(314) 349-1388

Citation History (2 surveys)

Survey - April 3, 2023

Survey Type: Special

Survey Event ID: JJ4J11

Deficiency Tags: D2016 D2016 D2096 D2004 D2096

Summary:

Summary Statement of Deficiencies D2004 ENROLLMENT CFR(s): 493.801(a)(3) For each specialty, subspecialty and analyte or test, participate in one approved proficiency testing program or programs, for one year before designating a different program and must notify CMS before any change in designation; This STANDARD is not met as evidenced by: Based on review of chemistry proficiency testing (PT) results reported to the CLIA database by the PT provider for 2022 and interview with the technical consultant (TC), the laboratory failed to participate in one approved proficiency testing program or programs, for one year before designating a different program. Findings: 1. Review of PT results for the first and second events of 2022 showed the laboratory enrolled with College of American Pathologists (CAP). 2. Review of PT results for the third event of 2022 showed the laboratory enrolled with American Proficiency Institute (API). 3. Interview with the technical consultant (TC) on March 28, 2023 at 8:15 AM confirmed the laboratory failed to participate in one approved proficiency testing program or programs, for one year before designating a different program. D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on review of chemistry proficiency testing (PT) results reported to the CLIA database by the PT provider for 2022/2023 and interview with the technical consultant (TC) on March 28, 2023 at 8:15 AM , the laboratory failed to successfully participate in PT. Refer to D-tag 2096, unsatisfactory performance in three out of four consecutive sodium PT challenges. D2096 ROUTINE CHEMISTRY CFR(s): 493.841(f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on review of chemistry proficiency testing (PT) results reported to the CLIA database by the PT provider for 2022/2023 and interview with the technical consultant (TC), the laboratory failed to achieve satisfactory performance for sodium in three out of four consecutive testing events. Findings: 1. Review of the chemistry- core PT results for the first event of 2022 showed the laboratory obtained an unsatisfactory score of 0 percent for the analyte sodium. 2. Review of the chemistry- core PT results for the second event of 2022 showed the laboratory obtained an unsatisfactory score of 0 percent for the analyte sodium. 3. Review of the chemistry- core PT results for the first event of 2023 showed the laboratory obtained an unsatisfactory score of 60 percent for the analyte sodium. 4. Interview with the technical consultant (TC) on March 28, 2023 at 8:15 AM confirmed the laboratory failed to achieve satisfactory performance for sodium in three out of four consecutive testing events. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - August 2, 2022

Survey Type: Standard

Survey Event ID: A5FE11

Deficiency Tags: D2016 D2096 D2096

Summary:

Summary Statement of Deficiencies D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on review of chemistry proficiency testing (PT) results for 2022 reported to the CLIA database by the PT provider and interview with the technical consultant (TC) on August 2, 2022, the laboratory failed to successfully participate in PT. Refer to D- tag 2096, unsatisfactory performance in two consecutive sodium PT challenges. D2096 ROUTINE CHEMISTRY CFR(s): 493.841(f) Failure to achieve satisfactory performance for the same analyte or test in two Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on review of chemistry proficiency testing (PT) results for 2022 and interview with the technical consultant (TC), the laboratory failed to achieve satisfactory performance for sodium in two consecutive testing events. Findings: 1. Review of the chemistry PT results for the first event of 2022 showed the laboratory obtained an unsatisfactory score of 0 percent for the analyte sodium. 2. Review of the chemistry PT results for the second event of 2022 showed the laboratory obtained an unsatisfactory score of 0 percent for the analyte sodium. 3. Interview with the technical consultant on August 2, 2022 at 10:30 AM confirmed the laboratory failed to achieve satisfactory performance for sodium in two consecutive testing events. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access